附近上门

Today鈥檚 medicine is more complex and data driven than ever, and is out to provide technology for to enable them to speed up development of tests and treatments.

Subscribe to the 附近上门 Daily

鈥淎ccess to precision medicine and diagnostics is uneven because there are many people who can鈥檛 afford it or it鈥檚 unavailable where they are,鈥� , CEO of Ovation, told 附近上门 News. 鈥淚f we can make development of specialized diagnostic tests faster and provide more access, the cost decreases and there are improved patient outcomes.鈥�

The Boston-based clinical informatics startup raised $21.5 million in Series B funding, led by , with participation from , , and industry veteran David Shaw.

Including the new round, Ovation has raised a total of $34.4 million in funding since the company was incorporated in 2017, which includes a in 2019, led by Madrona, according to 附近上门 News.

There are more than , but just several thousand specializing in molecular diagnostics, Wark said. In the last year, the company has doubled its customer base and experienced an increase of 200 percent in revenue. It is also working to connect all of the development data between labs and researchers.

鈥淲e are well positioned for molecular infectious diseases due to COVID-19 helping labs get off of the sidelines and test for this,鈥� Wark said. 鈥淭he last 10 months showed us that agility was lacking in health care, so we are doubling down on R&D, as well as new lines of testing, and working with new partners.鈥�

Ovation will continue to scale with the help of SignalFire, which Wark said focuses on companies in Ovation鈥檚 stage of growth.

, venture partner at SignalFire, said in an interview that he looks for companies combining software and data analytics to reimagine workflows. Ovation is doing that in the life sciences industry with molecular genomics labs by moving a specialized solution to the cloud, he added.

鈥淭hey need specialized software, and the real value is being able to stitch the data together, using Barry鈥檚 software, to create a solution to go after targeted therapeutics,鈥� Scoggins said. 鈥淚f the software is being used, then labs can coordinate and talk to each other in a better way to understand key questions.

鈥淛ust getting that data takes years and is costly,鈥� he added. 鈥淚f Ovation can shorten that time window, that is a lot of value–they will not only be successful, but shorten the timeframe for drugs to get to market.鈥�

Photo of Winston Brasor and Barry Wark, co-founders of Ovation, courtesy of Ovation
Blogroll illustration: